Adverse  ||| S:0 E:8 ||| JJ
reactions  ||| S:8 E:18 ||| NNS
to  ||| S:18 E:21 ||| TO
injectable  ||| S:21 E:32 ||| VB
fillers  ||| S:32 E:40 ||| VBN
The  ||| S:40 E:44 ||| DT
number  ||| S:44 E:51 ||| NN
of  ||| S:51 E:54 ||| IN
fillers  ||| S:54 E:62 ||| NN
grows  ||| S:62 E:68 ||| VBZ
constantly  ||| S:68 E:79 ||| RB
and  ||| S:79 E:83 ||| CC
allows  ||| S:83 E:90 ||| VBZ
responding  ||| S:90 E:101 ||| VBG
to  ||| S:101 E:104 ||| TO
an  ||| S:104 E:107 ||| DT
ever  ||| S:107 E:112 ||| RB
larger  ||| S:112 E:119 ||| JJR
demand  ||| S:119 E:126 ||| NN
with  ||| S:126 E:131 ||| IN
mostly  ||| S:131 E:138 ||| RB
hyaluronic  ||| S:138 E:149 ||| JJ
acid  ||| S:149 E:154 ||| NN
or  ||| S:154 E:157 ||| CC
collagen  ||| S:157 E:166 ||| NN
based  ||| S:166 E:172 ||| VBN
products ||| S:172 E:180 ||| NNS
.  ||| S:180 E:182 ||| .
However ||| S:182 E:189 ||| RB
,  ||| S:189 E:191 ||| ,
products  ||| S:191 E:200 ||| NNS
degrading  ||| S:200 E:210 ||| VBP
more  ||| S:210 E:215 ||| RBR
slowly ||| S:215 E:221 ||| RB
,  ||| S:221 E:223 ||| ,
containing  ||| S:223 E:234 ||| VBG
polylactic  ||| S:234 E:245 ||| JJ
acid  ||| S:245 E:250 ||| NN
or  ||| S:250 E:253 ||| CC
bioactive  ||| S:253 E:263 ||| JJ
ceramics ||| S:263 E:271 ||| NNS
.  ||| S:271 E:273 ||| .
All  ||| S:273 E:277 ||| PDT
these  ||| S:277 E:283 ||| DT
products  ||| S:283 E:292 ||| NNS
bring  ||| S:292 E:298 ||| VBP
in  ||| S:298 E:301 ||| IN
general  ||| S:301 E:309 ||| JJ
satisfactory  ||| S:309 E:322 ||| JJ
results ||| S:322 E:329 ||| NNS
.  ||| S:329 E:331 ||| .
Their  ||| S:331 E:337 ||| PRP$
short  ||| S:337 E:343 ||| JJ
term  ||| S:343 E:348 ||| NN
tolerance  ||| S:348 E:358 ||| NN
shows  ||| S:358 E:364 ||| VBZ
few  ||| S:364 E:368 ||| JJ
side  ||| S:368 E:373 ||| NN
effects ||| S:373 E:380 ||| NNS
,  ||| S:380 E:382 ||| ,
benign  ||| S:382 E:389 ||| JJ
and  ||| S:389 E:393 ||| CC
always  ||| S:393 E:400 ||| RB
reversible ||| S:400 E:410 ||| JJ
.  ||| S:410 E:412 ||| .
Long  ||| S:412 E:417 ||| JJ
term ||| S:417 E:421 ||| NN
,  ||| S:421 E:423 ||| ,
foreign  ||| S:423 E:431 ||| JJ
body  ||| S:431 E:436 ||| NN
granulomas  ||| S:436 E:447 ||| NNS
are  ||| S:447 E:451 ||| VBP
very  ||| S:451 E:456 ||| RB
rare  ||| S:456 E:461 ||| JJ
if  ||| S:461 E:464 ||| IN
interrogation  ||| S:464 E:478 ||| JJ
prior  ||| S:478 E:484 ||| JJ
to  ||| S:484 E:487 ||| TO
patient ||| S:487 E:494 ||| NN
's  ||| S:494 E:497 ||| POS
treatment  ||| S:497 E:507 ||| NN
is  ||| S:507 E:510 ||| VBZ
exhaustive ||| S:510 E:520 ||| VBN
.  ||| S:520 E:522 ||| .
On  ||| S:522 E:525 ||| IN
the  ||| S:525 E:529 ||| DT
reverse ||| S:529 E:536 ||| NN
,  ||| S:536 E:538 ||| ,
non  ||| S:538 E:542 ||| JJ
degradable  ||| S:542 E:553 ||| JJ
products  ||| S:553 E:562 ||| NNS
are  ||| S:562 E:566 ||| VBP
at  ||| S:566 E:569 ||| IN
the  ||| S:569 E:573 ||| DT
origin  ||| S:573 E:580 ||| NN
of  ||| S:580 E:583 ||| IN
unaesthetic  ||| S:583 E:595 ||| NN
and  ||| S:595 E:599 ||| CC
invalidating  ||| S:599 E:612 ||| JJ
granulomas ||| S:612 E:622 ||| NN
,  ||| S:622 E:624 ||| ,
often  ||| S:624 E:630 ||| RB
very  ||| S:630 E:635 ||| RB
delayed  ||| S:635 E:643 ||| VBN
and  ||| S:643 E:647 ||| CC
resisting  ||| S:647 E:657 ||| VBG
to  ||| S:657 E:660 ||| TO
various  ||| S:660 E:668 ||| JJ
local  ||| S:668 E:674 ||| JJ
treatments ||| S:674 E:684 ||| NNS
.  ||| S:684 E:686 ||| .
For  ||| S:686 E:690 ||| IN
this  ||| S:690 E:695 ||| DT
reason ||| S:695 E:701 ||| NN
,  ||| S:701 E:703 ||| ,
these  ||| S:703 E:709 ||| DT
products  ||| S:709 E:718 ||| NNS
should  ||| S:718 E:725 ||| MD
not  ||| S:725 E:729 ||| RB
be  ||| S:729 E:732 ||| VB
used  ||| S:732 E:737 ||| VBN
anymore  ||| S:737 E:745 ||| RB
or  ||| S:745 E:748 ||| CC
only  ||| S:748 E:753 ||| RB
very  ||| S:753 E:758 ||| RB
exceptionally ||| S:758 E:771 ||| RB
,  ||| S:771 E:773 ||| ,
for  ||| S:773 E:777 ||| IN
soft  ||| S:777 E:782 ||| JJ
tissue  ||| S:782 E:789 ||| NN
augmentation ||| S:789 E:801 ||| NN
.  ||| S:801 E:803 ||| .
